Search results
Showing 16 to 30 of 8114 results
Recommendation ID NG198/7 Question What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke
Our indicators measure outcomes that reflect quality of care. They also look at processes that are linked by evidence to improved outcomes. All our...
Our board sets out our strategic priorities and policies. The day to day decision-making is the responsibility of our executive team . The...
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Tell us about an interventional procedure you think should be assessed by NICE.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....
View recommendations for HTE18Show all sections